Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00394381

Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sponsor: National Medical Research Council (NMRC), Singapore

Conditions Acute Myeloid Leukemia Myelodysplastic Syndrome, High Grade

Interventions Infusion of autologous CIK cells

Updated 5 times since 2017 Last updated: Feb 9, 2017 Started: Oct 31, 2006 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Acute Myeloid Leukemia and Myelodysplastic Syndrome, High Grade, this trial is completed. The trial is conducted by National Medical Research Council (NMRC), Singapore and has accumulated 5 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Medical Research Council (NMRC), Singapore
Singapore General Hospital

Data source: Singapore General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore